Shopping Cart
Remove All
Your shopping cart is currently empty
CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC. CGP60474 is also a highly potent anti-endotoxemic agent and inhibits cyclin-dependent kinase (CDK) potently.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 2 mg | $40 | In Stock | In Stock | |
| 5 mg | $68 | In Stock | In Stock | |
| 10 mg | $98 | In Stock | In Stock | |
| 25 mg | $197 | In Stock | In Stock | |
| 50 mg | $349 | In Stock | In Stock | |
| 100 mg | $576 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $75 | In Stock | In Stock |
| Description | CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC. CGP60474 is also a highly potent anti-endotoxemic agent and inhibits cyclin-dependent kinase (CDK) potently. |
| Targets&IC50 | CDK7-CyclinH:200 nM, CDK5-p25:10 nM, CDK4-CyclinD:216 nM, CDK2-CyclinE:3 nM, CDK2-CyclinA:4 nM, CDK1-CyclinB:26 nM, CDK9-CyclinT:13 nM, VEGFR2:84 nM |
| In vitro | The IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/CyclinB, CDK2/CyclinE, CDK2/CyclinA, CDK5/p25, CDK7/CyclinH, CDK4/CyclinD and CDK9/cycT, respectively[4]. |
| In vivo | In the LPS endotoxemia model, CGP60474 (10?mg/kg; i.p.) inhibits the IL-6 level and increases the survival rate[3]. |
| Molecular Weight | 355.82 |
| Formula | C18H18ClN5O |
| Cas No. | 164658-13-3 |
| Smiles | OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1 |
| Relative Density. | 1.356g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (140.52 mM), Sonication is recommended. H2O: < 0.1 mg/mL (insoluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.62 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.